In kidney cancer (ccRCC), miR-184 suppresses proliferation, migration, and invasion through downregulation of CCND1 and targeting oncogenic pathways, although sponging by LINC01094 and SLC2A3 promotes tumour progression [46, 47]. Here, SLC2A3 is linked to neoplasm.